Lisata Therapeutics Inc (LSTA) — Smart Money Tracker (13F, Q2 2026)

LSTA ranks #7252 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

33 institutions disclose a position in LSTA, but none treat it as a major bet — even Rangeley Capital, LLC, its most concentrated holder, allocates just 0.3% of its own portfolio to it.

SBI Securities Co., Ltd. has trimmed its LSTA position for two straight quarters, cutting it by $25.0 while still holding $10.0.

LSTA reported a net loss of $14.6M over the trailing twelve months.

• Not yet profitable — net loss of $14.6M over the trailing twelve months
• Revenue declined 90.7% year over year
• Net income improved year over year, from -$18.9M to -$14.6M
• Operating cash flow was negative, using $15.9M in cash
• Current ratio of 5.76x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.21x equity — within a conventional range